The BioPharm Brief: Smarter Platforms, Safer Therapies, AI Acceleration

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today’s stories highlight a common trend emerging across the sector: companies are increasingly investing in platform technologies designed to make therapies more targeted, scalable, and efficient—from gene therapy delivery systems to artificial intelligence-enabled drug discovery tools.

First, JCR Pharmaceuticals presented new preclinical data at ASGCT 2026 supporting its JUST-AAV gene therapy platform, which is designed to improve delivery of therapies to the central nervous system while reducing unwanted liver exposure. The company reported encouraging findings in mouse models of neurodegenerative disorders including GM1 gangliosidosis and neuronal ceroid lipofuscinosis. Researchers observed improved CNS penetration, reduced neuroinflammation, and extended survival in treated animals. JCR says the platform could help address long-standing safety and delivery challenges associated with conventional AAV gene therapies.

Meanwhile, Hansa Biopharma announced an agreement worth up to $115 million with SERB Pharmaceuticals focused on expanding access to imlifidase, the company’s antibody-cleaving enzyme therapy. The deal centers on rare autoimmune and transplant-related conditions where pathogenic antibodies remain a significant barrier to treatment. The collaboration reflects continued interest in highly targeted biologic approaches capable of enabling transplantation and improving outcomes in difficult-to-treat patient populations.

And finally, Incyte and Edison Scientific unveiled a strategic collaboration aimed at integrating artificial intelligence across drug discovery and translational research workflows. Edison’s Kosmos AI platform will be embedded into Incyte’s R&D infrastructure to support target identification, biomarker analysis, and clinical data interpretation. The companies say the goal is to create a continuously learning system capable of improving research decisions over time by leveraging proprietary experimental and clinical datasets.

Taken together, today’s stories underscore how biopharma companies are increasingly pairing advanced biology with smarter enabling technologies to improve therapeutic precision, reduce toxicity risks, and accelerate development timelines.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• JCR Pharmaceuticals presented preclinical ASGCT 2026 data supporting CNS-targeted JUST-AAV gene therapy delivery with reduced liver exposure.

• Hansa Biopharma and SERB entered a licensing agreement focused on expanding access to imlifidase for transplant and autoimmune applications.

• Incyte partnered with Edison Scientific to integrate AI-driven predictive modeling across translational research and drug discovery workflows.